Literature DB >> 2158843

Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation.

J Raud1.   

Abstract

1. Intravital microscopy of the hamster cheek pouch was used to examine the influence of vasodilator prostanoids (prostaglandin E2 (PGE2), PGI2), forskolin, and nitroprusside on the microvascular changes during acute inflammation induced by antigen or histamine. The results extend our previous finding that PGE2 modulates allergic inflammation and histamine release in the cheek pouch model. 2. The microvascular actions of arachidonic acid and different cyclo-oxygenase products (PGE2, PGD2, PGI2, PGF2 alpha, and the thromboxane A2 (TXA2)-analogue U-44069) were first compared with respect to their effects on arteriolar tone. Of the prostaglandins, only PGE2 and PGI2 were potent vasodilators and markedly increased local blood flow. Nitroprusside and forskolin also caused vasodilatation and increased blood flow, but were somewhat less potent than PGE2 and PGI2. 3. Topically applied PGE2 and PGI2 in vasodilator concentrations suppressed the antigen-induced plasma leakage. On the other hand, although the antigen response was predominantly mediated by histamine, both prostaglandins enhanced the plasma leakage evoked by exogenous histamine. 4. In contrast, the vasodilator nitroprusside, in a dose causing an increase in blood flow equal to that of PGE2 and PGI2, potentiated both the histamine-induced plasma leakage, as well as the plasma and leukocyte extravasation after antigen challenge, indicating that the anti-inflammatory actions of the prostaglandins were unrelated to their vasodilator properties per se. 5. Because forskolin, a specific activator of adenylate cyclase, mimicked the actions of PGE2 and PGI2, i.e. inhibition of the antigen-induced plasma extravasation and enhancement of the histamine response, it is possible that the observed antiallergic effects of the prostaglandins were related to accumulation of intracellular adenosine 3': 5'-cyclic monophosphate (cyclic AMP). 6. Taken together, there appears to be a competition between pro- and anti-inflammatory effects of PGE2 and PGI2 in reactions involving release of endogeneous inflammatory mediators in vivo, i.e. enhancement of inflammatory mediator target action on one hand ('two mediator synergism'), and suppression of mediator release on the other. Moreover, the observations indicate that vasodilatation and inhibition of mediator release are two distinct actions of PGE2 and PGI2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158843      PMCID: PMC1917358          DOI: 10.1111/j.1476-5381.1990.tb12948.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Effects of known and suspected neurotransmitter substances and of some nucleotides on isolated mast cells.

Authors:  J A Kiernan
Journal:  Experientia       Date:  1972-06-15

2.  Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells.

Authors:  M Kaliner; K F Austen
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

3.  Effects of dibutyryl-3',5'-cyclic adenosine monophosphage, phosphodiesterase inhibitors and prostaglandin E1 on compound 48-80-induced histamine release from rat peritoneal mast cells in vitro.

Authors:  L J Loeffler; W Lovenberg; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1971-09       Impact factor: 5.858

4.  Prostaglandins as potentiators of increased vascular permeability in inflammation.

Authors:  T J Williams; J Morley
Journal:  Nature       Date:  1973-11-23       Impact factor: 49.962

5.  The preparation and use of the hamster cheek pouch for studies of the microcirculation.

Authors:  B R Duling
Journal:  Microvasc Res       Date:  1973-05       Impact factor: 3.514

6.  Modulation of slow-reacting substance of anaphylaxis and histamine release by prostacyclin and thromboxanes [proceedings].

Authors:  D M Engineer; P J Jose; P J Piper; J R Tippins
Journal:  J Physiol       Date:  1978-08       Impact factor: 5.182

7.  The hamster cheek pouch preparation as a model for studies of macromolecular permeability of the microvasculature.

Authors:  E Svensjö; K E Arfors; G Arturson; G Rutili
Journal:  Ups J Med Sci       Date:  1978       Impact factor: 2.384

8.  Intravital microscopic studies on acute mast cell-dependent inflammation.

Authors:  J Raud
Journal:  Acta Physiol Scand Suppl       Date:  1989

9.  Prostaglandin E2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked by in vivo challenge with compound 48/80 in the hamster cheek pouch.

Authors:  J Raud; A Sydbom; S E Dahlén; P Hedqvist
Journal:  Agents Actions       Date:  1989-08

10.  Prostaglandin I2 as a potentiator of acute inflammation in rats.

Authors:  K Komoriya; H Ohmori; A Azuma; S Kurozumi; Y Hashimoto; K C Nicolaou; W E Barnette; R L Magolda
Journal:  Prostaglandins       Date:  1978-04
View more
  5 in total

1.  Microvascular mechanisms of histamine-induced potentiation of leukocyte adhesion evoked by chemoattractants.

Authors:  H Thorlacius; J Raud; X Xie; P Hedqvist; L Lindbom
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia.

Authors:  C Bandeira-Melo; Y Singh; R S Cordeiro; P M e Silva; M A Martins
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

3.  Dissociation between the effects of zymosan on the systemic and pulmonary vessels of the rat.

Authors:  J Damas; D Lagneaux
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

4.  Role of prostanoids in the inflammatory reaction and their therapeutic potential in the skin.

Authors:  R Ekerdt; B Müller
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 5.  Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?

Authors:  Emad Al Jaaly; Mustafa Zakkar; Francesca Fiorentino; Gianni D Angelini
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.